Public Profile

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with unmet medical needs. Founded in 2006, the company has made significant strides in the pharmaceutical industry, particularly in the areas of drug delivery and formulation technologies. Specialising in the development of oral films and other unique delivery systems, Aquestive's core products, such as the Suboxone Film, stand out for their ability to enhance patient compliance and improve therapeutic outcomes. With a commitment to addressing complex medical challenges, the company has established a strong market position, recognised for its advancements in the treatment of opioid dependence and other conditions. Through its dedication to innovation, Aquestive Therapeutics continues to shape the future of patient care.

DitchCarbon Score

How does Aquestive Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Aquestive Therapeutics, Inc.'s score of 13 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.

80%

Aquestive Therapeutics, Inc.'s reported carbon emissions

Aquestive Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may be engaged in broader industry initiatives aimed at sustainability and reducing environmental impact. As the pharmaceutical sector increasingly focuses on climate action, it is essential for companies like Aquestive Therapeutics to establish clear emissions reduction strategies and commitments to align with global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Aquestive Therapeutics, Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Aquestive Therapeutics, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Aquestive Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Vectura Group Services Limited

GB
Chemicals nec
Updated 5 days ago
DitchCarbon Score

Labopharm Inc.

CA
Chemicals nec
Updated 5 days ago
DitchCarbon Score

Pacira BioSciences

US
Health and social work services (85)
Updated 5 days ago

DMK Pharmaceuticals Corporation

US
Chemicals nec
Updated 5 days ago

Talphera, Inc.

US
Chemicals nec
Updated 5 days ago

LTS Lohmann Therapie-Systeme AG

DE
Chemicals nec
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers